Skip to main content

Table 2 Malaria outcomes by treatment group

From: Effect of a single dose of oral azithromycin on malaria parasitaemia in children: a randomized controlled trial

 

Azithromycin

N (%) or median (IQR)

Placebo

N (%) or median (IQR)

Odds ratio or mean difference (95% CI)

P-value

Malaria parasitaemia

 14 days

44 (20.0%)

35 (17.0%)

1.22 (0.75 to 2.00)

0.43

 6 months

14 (7.6%)

10 (5.6%)

1.37 (0.59 to 3.16)

0.47

Parasite densitya

 14 days

188 (60 to 7087.5)

520 (120 to 5800)

− 0.44 (− 1.60 to 0.71)

0.45

 6 months

108 (64 to 540)

256 (88 to 790)

− 0.21 (− 1.55 to 1.12)

0.74

Gametocytaemia

 14 days

39 (17.7%)

31 (15.1%)

1.22 (0.73 to 2.04)

0.46

 6 months

14 (7.6%)

9 (5.1%)

1.53 (0.64 to 3.63)

0.34

Parasitaemia plus feverb

 14 days

7 (3.2%)

4 (1.9%)

1.66 (0.48 to 5.75)

0.43

 6 months

3 (1.6%)

1 (0.6%)

2.90 (0.30 to 28.2)

0.36

  1. IQR interquartile range CI confidence interval
  2. aAmong children with a positive smear, with models using a log transformation of parasite density
  3. bFever defined as tympanic temperature ≥ 37.5 °C